Introduction
AP-1 is a sequence-speci®c DNA binding transcription factor, which is composed of the fos and jun gene products (Angel and Karin, 1991) . The founding members of these two gene families, v-fos and v-jun, have originally been identi®ed as the transforming activities of the FBJ and FBR murine sarcoma virus (v-fos) Van Beveren et al., 1983) and avian sarcoma virus 17 (v-jun) (Bos et al., 1988) , respectively. The oncogenic activity of c-jun has been demonstrated in several experimental systems. Deregulated expression of c-Jun, or its viral counterpart v-Jun, can trigger transformation of avian and mammalian ®broblasts (Vogt, 1992) . c-jun expression in transgenic mice from an ubiquitous promoter (H2-c-junLTR) does not result in any apparent phenotype, but overexpression of v-jun causes wounding-induced ®brosar-comas (Schuh et al., 1990; Wang et al., 1995) . c-jun eciently cooperates with oncogenic ras in cellular transformation Smeal et al., 1991) and c-jun has been shown to be an important target of ras-mediated oncogenesis as ras-induced transformation is greatly reduced in the absence of c-jun (Johnson et al., 1996) . In addition, c-jun is also capable of cooperating with c-fos since osteosarcoma formation caused by c-fos overexpression (H2-cfosLTR) was enhanced in H2-c-fosLTR/H2-c-junLTR double transgenic mice (Wang et al., 1995) .
A number of stimuli including growth factors, tumour promoters and transforming oncoproteins augment AP-1 activity by stimulating mitogen-activated protein kinases (MAPKs) (Angel and Karin, 1996) . The c-Jun protein is phosphorylated at N-terminal serine residues 63 and 73 within the transactivation domain by the c-Jun N-terminal kinases (JNKs) (Derijard et al., 1994; Kyriakis et al., 1994) . C-Jun N-terminal phosphorylation (JNP) is believed to strongly augment c-Jun activity by recruiting the coactivator proteins CBP and p300 to target gene promoters resulting in increased gene transcription (Arias et al., 1994; Bannister et al., 1995) . Ras and several other oncoproteins stimulate phosphorylation of serines 63 and 73 (Derijard et al., 1994; Smeal et al., 1992; Smeal et al., 1991) , however, the function of JNP during oncogenic transformation has remained unclear.
We have previously reported the generation of mice and cells carrying a mutant c-jun allele with the JNK phosphoacceptor serines 63 and 73 changed to alanines (junAA) (Behrens et al., 1999) . Mice lacking JNP undergo normal embryonic development, but show defects in kainate-induced neuronal apoptosis (Behrens et al., 1999) . We have also shown that junAA primary mouse embryonic ®broblasts (MEFs) proliferate slowly, although the proliferation defect is not as severe as observed in c-jun7/7 MEFs (Behrens et al., 1999; Johnson et al., 1993; Schreiber et al., 1999) .
In this study we have tested the function of JNP during oncogenic transformation in vitro and in vivo. JNP was required for ecient transformation of immortalized ®broblasts by v-ras and v-fos, but not by v-src. To analyse the role of JNP in ras-mediated tumour formation in vivo, mice expressing a dominant form of the guanine nucleotide exchange factor SOS (Aronheim et al., 1994; Chardin et al., 1993) in the basal cells of the epidermis were employed (K5-SOS-F; Sibilia et al., 2000) . These mice develop skin papillomas with 100% penetrance in a wild-type background (Sibilia et al., 2000) , whereas in a junAA homozygous genetic background SOS-F-mediated tumour formation was delayed suggesting a function of JNP as a target of the ras pathway in keratinocytes. In addition, absence of JNP also resulted in decreased osteosarcoma formation in H2-c-fosLTR transgenic mice. These results provide genetic evidence that the absence of JNP reduces cellular transformation by the v-ras and v-fos oncogenes, but that the oncogenic activity of v-src is independent of JNP.
Results

Reduced fibroblast transformation by v-ras and v-fos in the absence of JNP
To study the function of JNP during oncogenic transformation in vitro, immortalized ®broblasts were derived from wild-type and junAA homozygous E12.5 fetuses. JunAA primary mouse embryonic ®broblasts (MEFs) entered senescence at the same time as wildtype control cells, and the duration of the crisis phase before the appearance of immortalized cells was similar to controls (data not shown). This is in contrast to c-jun7/7 MEFs, which undergo premature senescence and exhibit an extremely prolonged crisis phase . Immortalized 3T3 cell lines lacking JNP did not show a proliferation defect as junAA MEFs did (Behrens et al., 1999) (Figure 1a ). As immortalization occurs at least in part by mutation of genes encoding cell cycle regulators, JNP might control the activity of these proteins in MEFs, but this control mechanism is relieved in established ®broblasts.
To investigate the role of JNP in oncogenic transformation, two independent wild-type and two junAA immortalized 3T3 ®broblast cell lines were infected with recombinant retroviruses expressing vras, v-src or v-fos (Boulter and Wagner, 1988; Keller et al., 1985; Redmond et al., 1988; Wagner et al., 1985) . Whereas c-jun7/7 ®broblasts were resistant to morphological alterations induced by oncogenic Ras (Johnson et al., 1996) , junAA cells exhibited all characteristics of the transformed phenotype and were morphologically indistinguishable from wild-type controls in response to all three oncogenes tested ( Figure  1b) .
A functional assay for transformation is the ability to form tumours when injected into immunosuppressed mice. Whereas neo-expressing control and junAA cells did not form tumours, all oncogene-expressing wildtype 3T3 cells were tumorigenic (Figure 1c) . Absence of JNP considerably suppressed v-ras-induced tumour growth, but had no eect on v-src-expressing cells (Figure 1c ). The requirement for JNP was most dramatic in v-fos transformed cells. Nude mice injected with v-fos-infected wild-type ®broblasts developed large tumour masses and had to be sacri®ced 4 weeks after injection, when no visible or palpable tumours could be detected in v-fos-expressing junAA cells (Figure 1c) . Nevertheless, 16 weeks after injection these cells also gave rise to tumours (data not shown). Consistent with the results from tumour induction in nude mice, focus formation in vitro required both activated ras expression and JNP, since the number of foci formed in junAA cells was signi®cantly decreased, but v-srcinduced focus formation was normal (data not shown).
Consistent with previous observations, oncogenic ras strongly stimulated JNP (Figure 2a ). To a lesser extent also v-src and v-fos expression increased JNP in wildtype cells (Figure 2a ). Antibodies directed against the phosphorylated form of serine 63 of c-Jun failed to give a signal in all junAA cell lines, con®rming the absence of JNP. Moreover, there were no signi®cant dierences in the steady-state levels of the c-Jun protein among the various wild-type and junAA cell lines ( Figure 2a ). To determine the contribution of JNP to AP-1 transcriptional activity in the oncoprotein expressing cells, AP-1 activity was measured using a luciferase reporter gene construct containing ®ve AP-1 DNA binding sites (56TRE-Luc). AP-1 transcriptional activity was comparable in wild-type and junAA cells infected with the control virus ( Figure 2b ). Oncogenic ras elevated AP-1 activity 5 ± 6-fold in wild-type cells, but only 3 ± 4-fold in the absence of JNP. AP-1 induction by v-fos was slightly reduced in junAA cells, whereas v-src-expressing wild-type and junAA cells showed no signi®cant dierence in reporter gene activity (Figure 2b ). These results suggest that JNP is required for ecient transformation by v-fos and oncogenic ras.
JNP is required for efficient skin tumorigenesis caused by overexpression of a dominant form of hSOS
To determine the function of JNP as a target of cellular transformation by the Ras pathway in vivo, the skin tumour prone K5-SOS-F transgenic mice were bred into a homozygous junAA background (Sibilia et al., 2000) . C-jun is highly expressed in basal keratinocytes of the skin, the same cells that express the hSOS-F transgene (Rutberg et al., 1996; Sibilia et al., 2000) . The ®rst skin abnormalities induced by K5-SOS-F were visible already 2 weeks after birth in wild-type and junAA/+ mice and progressed into highly disorganized papillomatous structures, which in the tail region became more than 10 mm thick (data not shown). In addition, papillomas frequently occurred at the edges of tail-and toe-biopsy sites, suggesting that wounding was capable of contributing to tumour development (data not shown). The absence of JNP resulted in a delay of tumour formation.
Determination of the maximal tumour diameter at the age of 2 months showed an average decrease in tumour size by approximately 50% in a junAA background (Figure 3a) . However, wounding-induced papillomas and tumour progression occurred with unaltered frequency in these mice (data not shown). With increasing age (4 ± 6 months) larger tumour masses also developed in initially protected junAA homozygous mice (data not shown). Despite a signi®cant dierence in tumour size, analysis of junAA/+ and junAA/junAA tumours revealed no striking dierences in the histological appearance and cellular composition (Figure 3b) . Therefore, the absence of JNP delays but does not abolish skin tumour formation induced by the hSOS-F transgene. Inhibition of c-fos-induced bone tumour formation in junAA homozygous mice
We next studied the eect of JNP on c-fos-induced skeletal osteosacomas (Grigoriadis et al., 1993) . H2-c-fosLTR transgenic mice in a junAA/+ heterozygous and in a junAA homozygous background were generated and the spatial and temporal course of osteosarcoma development was studied using skeletal X-ray analysis (Figure 4a ). Radiographic examination revealed that the spatial distribution of tumours and the onset of tumour formation were comparable in mice carrying the H2-c-fosLTR transgene in a junAA homozygous and heterozygous background (7.7+2.1 and 8.2+2.1 weeks, respectively) (Figure 4b ). Only at older age a modest dierence in tumour onset became apparent. Whereas all control mice had developed radiographically detectable tumours by the age of 3 months (15/15), 4/18 (22%) junAA homozygotes were still tumour-free at this timepoint (Figure 4b) . To quantify the eect of JNP on osteosarcoma formation, the number of tumours in H2-c-fosLTR transgenic junAA/junAA and junAA/+ mice was determined. The absence of JNP resulted in impaired tumour development since the mean tumour numbers at 2, 3 and 4 months of age were reduced and the tumours were on average smaller in size (Figure 4a,c) .
Bone tumours of both junAA homozygous and heterozygous H2-c-fosLTR transgenic mice (n=17 and n=18, respectively) showed the morphological features of low-grade chondroblastic osteosarcomas. The tumours were largely composed of mineralized neoplastic bone lined by tumour cells with osteoblastic dierentiation (Figure 4d,f) . Areas of anaplastic tumour morphology were not detected. Staining for acid mucopolysaccharide (Alcian blue) indicated the presence of areas of chondroblastic dierentiation, which were comparable in junAA homozygous and heterozygous tumours (data not shown). Furthermore, histochemical staining for tartrate-resistant acid phosphatase (TRAP), a marker for osteoclasts, revealed that comparable numbers of TRAP-positive multinucleated cells lined the bone surfaces of junAA homozygous and heterozygous tumours suggesting that bone turnover was not aected (data not shown).
To determine whether absence of JNP had an eect on the proliferation of the tumour cells, Bromodeoxyuridine (BrdU) incorporation detected by immunohistochemistry was used to measure the number of S phase cells. Proliferating tumour cells were predominantly located in the vicinity of the tumour surface and were hardly detected in the central part, which consists primarily of mineralized bone matrix (Figure 4e,g ). Whereas 6.2% of the tumour cells in a junAA/+ background had gone through S phase within the 12 h labelling period, the number of proliferating cells was decreased by *30% in the absence of JNP (Figure 4h) . Therefore, it is tempting to speculate that the reduced proliferation capacity of these cells might be responsible for the decreased tumour number and size observed in junAA homozygous mice.
Discussion
Although it has been noted previously that JNP is stimulated by a number of oncogenes, the functional signi®cance and contribution of JNP to the transformed phenotype has been unclear. This study demonstrates that absence of JNP does not aect the oncogenic activity of v-src, but reduces transformation by components of the Ras pathway and by oncogenic fos both in vitro and in vivo although both ras and fos are still capable of transforming junAA cells.
Ras and fos have dierent biological activities and biochemical interactions with JNP. Ras activates the JNKs and thereby JNP resulting in increased AP-1 activity. Since oncogenic ras activates multiple other eector molecules including Raf and PI3-kinase (Joneson and Bar-Sagi, 1997) , our results suggest also a role of the JNK pathway as a downstream target of ras during oncogenesis. However, lack of JNP has a milder eect on ras-induced transformation compared to the complete absence of c-jun (Johnson et al., 1996) . c-jun7/7 ®broblasts are completely resistant to ras transformation (Johnson et al., 1996) , whereas the JunAA protein is still capable of signi®cantly contributing to ras-mediated oncogenesis. Therefore, JNP contributes to but is not required for ecient cooperation between ras and c-jun. One explanation for this observation is that JNP is required for the maximal transcriptional induction of target genes involved in oncogenic transformation. The JunAA protein might still stimulate transcription at a low level, whereas complete absence of c-Jun would abolish gene induction. Alternatively, c-Jun and phospho-c-Jun may regulate dierent sets of target genes which both contribute to ras-induced oncogenesis. N-terminal phosphorylation of c-Jun could result in the recruitment of dierent coactivator proteins thereby altering the activity and target gene speci®city of c-Jun. It was reported that expression of a junAA allele in ras expressing c-jun7/7 cells rescued soft-agar colony formation, but not tumorigenicity, which may argue in favour of the latter possibility (Johnson et al., 1996) .
We have chosen skin tumorigenesis as a model system to test the signi®cance of JNP as a target of Ras in vivo. Since activating mutations of ras occur frequently during human skin carcinogenesis, the identi®cation of Ras downstream eectors in keratinocytes is of medical relevance (Yuspa, 1998) . Using chemically induced papillomas as a model of skin carcinogenesis it was shown that the formation of papillomas was unaected in c-fos knock-out mice, but that benign-to-malignant progression was severely impaired (Saez et al., 1995) . In contrast, c-jun has been implicated in papilloma formation since transgenic mice expressing a dominant negative allele of cjun (TAM67) in basal keratinocytes show greatly decreased numbers of chemically induced papillomas (Young et al., 1999) . Similarly, in the K5-SOS-F transgenic model, the absence of JNP delayed tumour formation, but the eventual progression to large tumour masses was not aected. These results indicate that c-jun and c-fos may have dierent functions during ras-induced skin cancerogenesis: c-jun and JNP appear to be required for papilloma formation, a process that is c-fos-independent. Only at later stages of tumour development, when malignant progression occurs, c-fos is essential. Whether these dierences are indicative of dierent biological activities of c-fos and c-jun during skin carcinogenesis or are due to the dierent tumour models used requires further investigation. In contrast to skin tumours, injury-induced papillomas showed similar growth kinetics in junAA and control mice. Wounds are known to activate a number of growth factors and cytokines and thereby contribute to tumour development (Rappolee et al., 1988) . The function of JNP in tumour induction, which results in a delay of papilloma formation in K5-SOS-F transgenic mice, may be bypassed by a wounding-induced event explaining normal papilloma formation at the sites of injury in the absence of JNP.
Whereas Ras directly stimulates JNP, overexpression of oncogenic fos results in elevation of AP-1 activity by recruiting and binding to dimerization partners, most likely Jun proteins, thereby forming a functional AP-1 transcription factor complex Bravo, 1991, 1992) . It has been shown previously by generating double transgenic lines that c-jun is capable of cooperating with fos during oncogenesis (Wang et al., 1995) , our data demonstrate that endogenous c-Jun is an important partner for oncogenic Fos during cellular transformation. In particular, N-terminal phosphorylation of c-Jun appears to be required for the activity of c-Fos/cJun heterodimeric complexes in transgenic osteoblasts. The partial suppression of osteosarcoma formation in the absence of JNP may be explained by a reduction of tumour cell proliferation. c-Jun and JNP have been shown to regulate cellular proliferation in several types including ®broblasts and hepatocytes (Behrens et al., 1999; Eferl et al., 1999; Johnson et al., 1993; Schreiber et al., 1999; Wisdom et al., 1999) . Moreover, c-jun is highly expressed in c-fos transgenic osteoblasts (Grigoriadis et al., 1993 ) and JNP appears to contribute to c-Jun's function in controlling the proliferation of these transformed cells.
In humans, osteosarcoma is the second most common neoplasm of bone after myeloma, and accounts for approximately 20% of all primary malignant bone tumours. C-fos is ampli®ed in a signi®cant number of osteosarcomas and alterations of c-fos correlate with a bad prognosis, since they occur more frequently in patients with recurrent or metastatic disease (Pompetti et al., 1996) . The ®nding that JNP contributes to oncogenic transformation and tumour growth suggests that inhibition of JNP could be a novel therapeutic principle to interfere with tumour growth and disease progression, particularly in patients with osteosarcomas and skin tumours.
Materials and methods
Mice
Mice carrying a mutant c-jun allele, which has the JNK phosphoacceptor serines 63 and 73 mutated to alanines, were generated using homologous recombination in ES cells as described (Behrens et al., 1999) . The H2-c-fosLTR transgenic line (Grigoriadis et al., 1993) and the K5-SOS-F line (Sibilia et al., 2000) are described elsewhere.
Cells and viruses
Immortalized cell clines were derived from wild-type (3T3AA25 and 3T3AA30) and junAA homozygous (3T3AA28 and 3T3AA29) E12.5 fetuses according to the 3T3 protocol (Todaro et al., 1965) . The following retroviruses were used for transformation assays: C2-she-ras (LTR-Ha-vras); SR1 (LTR-neo TK-v-src); C2-v-fos (LTR-neo TK-vfos); and N2/C2 (LTR-neo) (Boulter and Wagner, 1988; Keller et al., 1985; Redmond et al., 1988; Wagner et al., 1985) . There was no dierence in the infection frequency between wild-type and junAA cells (data not shown).
Focus formation assay
Wild-type and junAA/junAA immortalized ®broblasts were plated at a density of 3610 5 cells per 10 cm dish and infected with the above-described retroviruses the next day. Cells were cultured in the same dishes without selection for 2 weeks. Thereafter, the medium was removed, plates were washed with PBS, ®xed with methanol and stained with 0.2% methylene blue (v/v in methanol). The number of macroscopically visible foci was estimated by visual examination.
Tumorigenic assay
Wild-type and junAA/junAA immortalized ®broblasts were plated at a density of 3610 5 cells per 10 cm dish, and infected with the above-described retroviruses the next day. Cells were cultured in the same dishes in the presence of 1 mg/ml G418 for 1 week until all non-infected cells had died. 2610 5 subcon¯uent G418-resistant cells were subcutaneously injected into 3 ± 5 week old anaesthetized nude mice. The mice were monitored weekly for the appearance of tumours.
Histology and BrdU immunohistochemistry
Mice of various genotypes were injected intraperitoneally with 100 mg of bromodeoxyuridine (BrdU) per gram of body weight 12 h prior to sacri®ce. Tumour tissues were ®xed in 4% formaldehyde, dehydrated, embedded in paran and sectioned (5 mm). Calci®ed tissues were decalci®ed in EDTA (0.5 M, pH 7.6) for 5 ± 10 days prior to embedding. For histological analysis sections were stained with Harris haematoxylin and eosin (Sigma). For BrdU immunohistochemistry sections pretreated with protease type XXIV and 2 M HCl were incubated with biotinylated mouse monoclonal anti-BrdU antibody (Caltac; 1 : 50 dilution) at 48C overnight. The signal was ampli®ed with the Vectastain ABC Kit (Vector Laboratories) and visualized with 3, 3'-diaminobenzidine (Vector Laboratories); sections were counterstained with Harris haematoxylin (Sigma).
Western blot analysis
Cell extracts from ®broblasts of various genotypes were prepared as described (Behrens et al., 1999) . Between 100 and 200 mg of cell extracts were used for Western blot analysis according to standard procedures (Sabapathy et al., 1999) . Brie¯y, the extracts were separated on SDS polyacrylamide gels, transferred onto Immobilon-P membrane (Millipore) and probed with anti-phospho-c-Jun (from M Yaniv), anti-cJun (Transduction Laboratories) and anti-bactin (Sigma) antibodies. Immunoreactive bands were visualized using the Enhanced Chemoilluminescence (ECL) kit (Boehringer Mannheim) according to the manufacturer's recommendations.
Reporter gene assay
Wild-type (3T3AA25 and 3T3AA30) and junAA homozygous (3T3AA28 and 3T3AA29) ®broblasts cells lines were cotransfected with a luciferase reporter gene regulated by a pentameric AP-1 site (56TRE-Luc) and CMV-LacZ (transfection control). Cell extracts were harvested 16 h after transfection. Each value represents the mean+s.e.m. of two independent clones of each genotype measured in duplicate.
